Dr. John M. Feigert's Credentials

Accepting New Patients

Yes, this doctor is accepting new patients

Biography

With a specific interest in teaching, Dr. Feigert has held several instructional positions throughout his career. After earning his Medical Degree from the Cornell University School of Medicine, he spent a year as an Instructor of Medicine at the Cornell University Medical College and another year as the Medical Director of the Division of Oncology at Elliot Hospital in Manchester, New Hampshire. Dr. Feigert has also served as a Clinical Assistant Professor at Georgetown University Medical Center and at the Virginia Commonwealth University’s INOVA Fairfax campus. Dr. Feigert has been recognized as a Top Doctor in both Northern Virginia Magazine and Washingtonian magazine. He has also been recognized by the Alpha Omega Alpha Honor Medical Society. Dr. Feigert is a member of several professional organizations including the American Society of Clinical Oncology, the American Society of Hematology and the Arlington County Medical Society. He is actively involved in local tumor boards, and he supports international communities through his participation with the Virginia Hospital Center Medical Brigade, a volunteer organization that helps bring clean water and health care to areas in Honduras. During his spare time, Dr. Feigert is an active tennis player.

Languages

• Spanish
• English

Education

• Harvard University (Grad. 1979)
• Cornell University Medical College (Grad. 1983)

Other Specialties

• Oncologist / Hematologist

Areas of Expertise

• Genitourinary Cancer (urologic Cancer)
• Leukemia
• Lymphoma

Awards & Recognitions

• Northern Virginia Magazine Top Doctor 2018
• Washingtonian Magazine Top Doctors 2020
• Washingtonian Magazine Top Doctor 2014
• Northern Virginia Magazine Top Doctor 2015
• Washingtonian Top Doctor 2015
• Northern Virginia Magazine Top Doctor 2014
• Top Doctors Virginia Living Magazine 2018
• 2018 Washingtonian Magazine Top Doctor Nomination
• Washingtonian Top Doctor 2016
• Northern Virginia Magazine Top Doctor 2019

Publications & Research

• A Comparison of Efficacy of Sargramostim (yeast-derived Rhu GM-CSF) and Filgrastim (Bacteria-derived Rhu G-CSF) in the Therapeutic Setting of Chemotherapy-induced Myelosuppression.
• Rapidly Progressive Prostate Cancer in the Primary Care Setting.
• Deferasirox (ICL670; Exjade) Reduces Serum Ferritin and Labile Plasma Iron in Patients with Myelodsyplastic Syndromes.
• Porcine Factor VIII Controls Severe Bleeding in Acquired Von Willebrand's Disease By Supplying Von Willebrand's Factor.
• Multicentric Angiofollicular Lymph Node Hyperplasia with Peripheral Neuropathy, Pseudotumor Cerebri, IgA Dysproteinemia, and Thrombocytosis in Women: A Distinct Clinicopathology Entity.
• Tissue Plasminogen Activator Binds to Immobilized Immunoglobulin G: Enhancement by Plasmin and the Identification of Plasmin Derived Fab as the t-PA Binding Fragment.
• Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion-Dependent Patients with Myelodysplastic Syndrome.
• Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial
• Iron Chelation with Deferasirox (Exjade®) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS)
• Randomized Trial Comparing the Tolerability of Sargramostim (yeast-derived RhuGM-CSF) and Filgrastrim (Bacteria-derived RhuG-CSF) in Cancer Patients Receiving Myelosuppressive Chemotherapy.
• Oncologists’ Experience in Reporting Cancer Staging and Guideline Adherence: Lessons From the 2006 Medicare Oncology Demonstration.